Edition:
India

Altimmune Inc (ALT.OQ)

ALT.OQ on NASDAQ Stock Exchange Global Market

0.58USD
21 Jun 2018
Change (% chg)

$-0.04 (-6.41%)
Prev Close
$0.62
Open
$0.62
Day's High
$0.62
Day's Low
$0.58
Volume
26,181
Avg. Vol
80,472
52-wk High
$3.98
52-wk Low
$0.42

Chart for

About

Altimmune, Inc., formerly Pharmathene, Inc., is a clinical-stage immunotherapeutic company. The Company focuses in development of medical counter measures against biological and chemical threats. The Company is involved in development of two next generation anthrax vaccines. It has two proprietary platform technologies,... (more)

Overall

Beta: 2.96
Market Cap(Mil.): $35.38
Shares Outstanding(Mil.): 15.59
Dividend: 29.10
Yield (%): --

Financials

BRIEF-Altimmune Announces Positive Data From Its Phase 2A Study Of Nasovax Intranasal Influenza Vaccine

* ALTIMMUNE ANNOUNCES POSITIVE DATA FROM ITS PHASE 2A STUDY OF NASOVAX INTRANASAL INFLUENZA VACCINE AND PROVIDES AN UPDATE ON ITS PHASE 1B STUDY OF HEPTCELL TARGETED IMMUNOTHERAPY IN CHRONIC HEPATITIS B INFECTION

27 Mar 2018

BRIEF-Altimmune Announces Pre-Clinical Data From Its Sparvax-L Anthrax Vaccine Program

* ALTIMMUNE ANNOUNCES PRE-CLINICAL DATA FROM ITS SPARVAX-L ANTHRAX VACCINE PROGRAM

13 Mar 2018

BRIEF-Hudson Bay Capital Management Reports A 9.99 Percent Passive Stake In Altimmune

* HUDSON BAY CAPITAL MANAGEMENT LP‍ REPORTS A 9.99 PERCENT PASSIVE STAKE IN ALTIMMUNE, INC​ AS OF DECEMBER 31, 2017 - SEC FILING Source text for Eikon: [http://bit.ly/2nwUAiB] Further company coverage:

02 Feb 2018

BRIEF-Altimmune Announces Allowance On Patent Covering Use Of Nasoshield In U.S.

* ALTIMMUNE ANNOUNCES NOTICE OF ALLOWANCE ON PATENT COVERING USE OF NASOSHIELD IN THE U.S. Source text for Eikon: Further company coverage:

23 Jan 2018

BRIEF-Altimmune Elects Mitchel Sayare As Chairman Of Its Board

* ALTIMMUNE ELECTS MITCHEL SAYARE, PH.D. AS CHAIRMAN OF ITS BOARD OF DIRECTORS

03 Jan 2018

Competitors

Earnings vs. Estimates